Abiraterone Acetate | ≥99%(HPLC) | Selleck | P450 (e.g. CYP17) inhibitor
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Steroid synthesis pathway and aromatization. Abiraterone is a novel... | Download Scientific Diagram
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. - Abstract - Europe PMC
CYP17A1 - an overview | ScienceDirect Topics
P450 Signaling | CYP450
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective - ScienceDirect
CYP17A1 inhibitor - Wikipedia
Abiraterone (Zytiga): Mechanism of Zytiga
Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation. | Semantic Scholar
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential | Semantic Scholar
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer | Scientific Reports
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
Abiraterone, CYP17 inhibitor Abiraterone (CB-7598)-Xcessbio Biosciences Inc
Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1 | Drug Metabolism & Disposition
Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy - Njar - Translational Cancer Research
